People
A multi-day conference hosted by Biogen during the early days of the COVID-19 pandemic has been determined to be a super-spreader event, with more than 300,000 infections linked to the conference.
In phase one of the two-part program, access to tofersen will be granted on an individual basis to SOD1-ALS patients with an ALS Functional Rating Scale - Revised (ALSFRS-R) slope decline greater than or equal to 2 points per month.
As vaccinations against COVID-19 continue across the U.S., there appears to be an increase in cases in younger populations.
As a devastating pandemic increased scientific collaboration globally, CSL was already ahead of the curve with teams spanning the continents, working together to advance lifesaving treatments and technologies.
Executives at pharmaceutical companies are known for receiving large salaries. When bonuses and stock options are factored into the picture, their annual compensation can jump into the range of tens of millions of dollars, like Pfizer’s Albert Bourla, Alex Gorsky from Johnson & Johnson, and AstraZeneca’s Pascal Soriot.
A new study suggests that many patients with long-term COVID-19 symptoms still experience health issues six months following infection, are survivors with “long haul” disease have a greater risk of dying and use a more significant number of medications than patients who have fully recovered from the virus.
Biopharma and life sciences companies strengthen their boards and leadership teams with these Movers & Shakers.
BioSpace recently spoke with Norman Sussman, chief medical officer at DURECT, a company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and lifesaving therapies based on its endogenous epigenetic regulator program.
BioSpace spoke with Paula Ragan, CEO and President of X4 Pharmaceuticals, a company focused on restoring healthy immune system function in people with rare diseases.
Several prominent investors are urging shareholders to reject the compensation package because it shields the executive from billions of dollars in opioid-related litigation costs to the company.
PRESS RELEASES